Alex Azar's job hop from drugmaker Eli Lilly to the Trump administration reflects ever-deepening ties between the pharmaceutical industry and the federal government. A Kaiser Health News analysis shows that hundreds of people have glided through the "revolving door" that connects the drug industry to Capitol Hill and to the Department of Health and Human Services.